People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Enveric Biosciences, Inc. | — | Pharmaceuticals | Series A | $37.6M | $3.7M | 2022 |
Dr. Bob Dagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dr. Bob Dagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Dimitrios Angelis | 1 | 3 |
| Joseph Tucker | 1 | 3 |
| David Luci | 1 | 3 |
| Robert Shawah | 1 | 2 |
| Kevin Coveney | 1 | 2 |
| Douglas Lind | 1 | 2 |
| Jeffrey Eberwein | 1 | 2 |
| Robert Pearse | 1 | 2 |
| Viraj Patel | 1 | 2 |
| Brent Kelton | 1 | 2 |
| Michael D. Webb | 1 | 2 |
| Carter Ward | 1 | 2 |
| Avani Kanubaddi | 1 | 1 |
| Dr. Marcus Schabacker | 1 | 1 |
| Bevin O'Niel | 1 | 1 |
| Sol Mayer | 1 | 1 |
| Peter Facchini, PhD | 1 | 1 |
| Dr. Douglas Lind | 1 | 1 |
| Joseph Tucker, PhD | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.